Literature DB >> 2913410

Identification and implications of new types of mineralocorticoid hypertension.

E G Biglieri1, I Irony, C E Kater.   

Abstract

200 patients with mineralocorticoid hypertension were studied at the Clinical Study Center. The study of 150 patients with primary aldosteronism revealed five distinct subsets based on their responses to the upright posture, after administration of intravenous saline, deoxycorticosterone acetate, and spironolactone. Two new types were identified--aldosterone producing responsive adenoma (AP-RA) and primary adrenal hyperplasia (PAH). Patients with AP-RA maintained normal physiologic responses to the above maneuvers. Patients with PAH had responses similar to patients with an aldosterone producing adenoma (APA) but no tumor was identified. Both types were cured by unilateral adrenalectomy. There has been no change in subtype in up to 20 years of follow-up. The notion of a continuum from low renin hypertension to APA is not supported. Primary deoxycorticosteronism caused by a benign adrenal adenoma, malignancy and hyperplasia is described. Uniquely, overproduction of the 17-deoxysteroids of the zona fasciculata occurs with normal 17-hydroxy function. After the removal of a benign adenoma the contralateral adrenal gland revealed a delay in the 17-deoxysteroid responses to ACTH in the face of normal cortisol increases. This suggests that an independent pituitary regulator of the 17-deoxypathway may exist. Other hypertensive disorders with excessive deoxycorticosterone production are linked with increases of ACTH and cortisol levels. The hallmarks of primary deoxycorticosteronism are hypertension with hypokalemia, suppression of renin and aldosterone, and overproduction of the 17-deoxysteroids.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2913410     DOI: 10.1016/0022-4731(89)90164-7

Source DB:  PubMed          Journal:  J Steroid Biochem        ISSN: 0022-4731            Impact factor:   4.292


  7 in total

1.  A subtype prediction score for primary aldosteronism.

Authors:  K Nanba; M Tsuiki; K Nakao; A Nanba; T Usui; T Tagami; Y Hirokawa; H Okuno; T Suzuki; T Shimbo; A Shimatsu; M Naruse
Journal:  J Hum Hypertens       Date:  2014-04-03       Impact factor: 3.012

Review 2.  Cellular origin of aldosteronomas.

Authors:  A Ganguly
Journal:  Clin Investig       Date:  1992-05

3.  Idiopathic hyperplasia of the adrenal gland behaving like an aldosterone producing adenoma.

Authors:  A Rao; J C Melby
Journal:  J Endocrinol Invest       Date:  1997-01       Impact factor: 4.256

Review 4.  Progress in primary aldosteronism: present challenges and perspectives.

Authors:  C E Gomez-Sanchez; G P Rossi; F Fallo; M Mannelli
Journal:  Horm Metab Res       Date:  2010-01-20       Impact factor: 2.936

5.  Role of endogenous ACTH on circadian aldosterone rhythm in patients with primary aldosteronism.

Authors:  Takuhiro Sonoyama; Masakatsu Sone; Naohisa Tamura; Kyoko Honda; Daisuke Taura; Katsutoshi Kojima; Yorihide Fukuda; Naotetsu Kanamoto; Masako Miura; Akihiro Yasoda; Hiroshi Arai; Hiroshi Itoh; Kazuwa Nakao
Journal:  Endocr Connect       Date:  2014-12       Impact factor: 3.335

Review 6.  Role of ACTH and Other Hormones in the Regulation of Aldosterone Production in Primary Aldosteronism.

Authors:  Nada El Ghorayeb; Isabelle Bourdeau; André Lacroix
Journal:  Front Endocrinol (Lausanne)       Date:  2016-06-27       Impact factor: 5.555

7.  Evaluation of the (1-24) adrenocorticotropin stimulation test for the diagnosis of primary aldosteronism.

Authors:  Ken Terui; Kazunori Kageyama; Takeshi Nigawara; Takako Moriyama; Satoru Sakihara; Shinobu Takayasu; Yuko Tsushima; Yutaka Watanki; Satoshi Yamagata; Aya Sugiyama; Shingo Murasawa; Yuki Nakada; Toshihiro Suda; Makoto Daimon
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2016-03-23       Impact factor: 1.636

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.